The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that the ministry approved GC Biopharma’s ‘Livmarli (maralixibat chloride)’ on the 28th. Livmarli is an imported rare disease drug used to treat cholestatic pruritus in patients with Alagille syndrome who are 1 year of age and older.

Alagille syndrome is a rare genetic disorder in which bile builds up in the liver and does not flow out due to reduced number of bile ducts inside the liver. It can also cause cardiovascular, skeletal, ocular, and dermatological complications.

According to the Health Insurance Review and Assessment Service data, there were currently 136 patients diagnosed with Alagille syndrome in Kor